STOCK TITAN

Avalyn Pharma (AVLN) SEC Filings, Apr 29, 2026

AVLN NASDAQ
Rhea-AI Summary

Avalyn Pharma Inc. executive Carlson Douglas R filed an initial Form 3 showing stock option holdings in the company. He holds options to acquire 83,576 shares of common stock at an exercise price of $4.81 per share, expiring on September 10, 2035, and options on 270,498 shares at $4.62 per share, expiring on June 10, 2034.

For the $4.81 options, 25% of the underlying shares vested on May 1, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. For the $4.62 options, 25% vest on May 29, 2026, with the balance also vesting in 36 monthly installments, contingent on his continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Avalyn Pharma Inc. filed an initial insider ownership report for its General Counsel, Adam H. Golden. The Form 3 lists him as an officer but does not report any share transactions or derivative positions, indicating this filing is purely administrative disclosure of insider status rather than trading activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
CERT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
certification

FAQ

How many Avalyn Pharma (AVLN) SEC filings are available on StockTitan?

StockTitan tracks 43 SEC filings for Avalyn Pharma (AVLN). Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Avalyn Pharma (AVLN)?

The most recent SEC filing for Avalyn Pharma (AVLN) was filed on November 19, 2026.